Advertisement
Advertisement
AKBA
Akebia Therapeutics, Inc.
1.39
USDSponsored
0.00
-0.36%
Mar 26, 15:24 UTC -4
Closed
After-Market
1.37
-0.01
-0.79%
AKBA Earnings Reports
Positive Surprise Ratio
AKBA beat 18 of 41 last estimates.
44%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$53.00M
/-$0.03
Implied change from Q4 25 (Revenue/ EPS)
-8.03%
/-40.00%
Implied change from Q1 25 (Revenue/ EPS)
-7.57%
/-200.00%
Akebia Therapeutics, Inc. earnings per share and revenue
On Feb 26, 2026, AKBA reported earnings of -0.05 USD per share (EPS) for Q4 25, missing the estimate of -0.02 USD, resulting in a -96.08% surprise. Revenue reached 57.62 million, compared to an expected 47.02 million, with a 22.56% difference. The market reacted with a +9.09% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.03 USD, with revenue projected to reach 53.00 million USD, implying an decrease of -40.00% EPS, and decrease of -8.03% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Vivani Medical, Inc. Common Stock (DE)
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.09
Surprise
-
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Acrivon Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.47
Actual
-$0.52
Surprise
-9.34%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
What were Akebia Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Akebia Therapeutics, Inc. reported EPS of -$0.05, missing estimates by -96.08%, and revenue of $57.62M, 22.56% above expectations.
How did the market react to Akebia Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved up 9.09%, changed from $1.21 before the earnings release to $1.32 the day after.
When is Akebia Therapeutics, Inc. expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Akebia Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Akebia Therapeutics, Inc. is expected to report EPS of -$0.03 and revenue of $53.00M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement